Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.
Advertisement
Follow the links below to read about each product:
Articles in this issue
over 1 year ago
Pharmaceutical Executive: July/August 2024 Issue (PDF)over 1 year ago
An AI Pulse Checkover 1 year ago
A Promising Option: Exxuaover 1 year ago
Opening the Door: Omvohover 1 year ago
'Marked’ for Stardom?: Truqapover 1 year ago
Branching Off: Wegovyover 1 year ago
A Formidable First: Winrevairover 1 year ago
The Future of Launch Excellence is Generative AIover 1 year ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'over 1 year ago
Big Bets, Bold StepsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
